Eye drop formulation useful for treating lesions of corneal epithelium
Patent 5145680 Issued on September 8, 1992. Estimated Expiration Date: 
October 9, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
October 9, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorAssigneeApplicationNo. 594094 filed on 10/09/1990US Classes:424/427, Ocular424/422, Implant or insert514/8, Glycoprotein (carbohydrate containing)514/912, OPHTHALMIC514/914, Inflammation514/915, Wetting agent530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/830Plasma; serumExaminersPrimary: Page, Thurman K.Assistant: Azpuru, Carlos Attorney, Agent or FirmForeign Patent References
International ClassesC07K 001/02C07K 015/06 Foreign Application Priority Data1989-02-13 JPAbstractVitronectin produces very high therapeutic effects upon injuries of the corneal epithelium. When applied to lesions of the corneal epithelium in the form of eye drops, Vitronectin induces rapid cure of the lesions with regeneration of normal cells. Moreover Vitronectin can be sterilized by autoclaving.Other References
|
| ||||||||||||||
